Company Information
CIN
Status
Date of Incorporation
14 December 1987
State / ROC
/ ROC Hyderabad
Last Balance Sheet
31 March 2023
Last Annual Meeting
Paid Up Capital
84,652,030
Authorised Capital
120,000,000
Directors
Srinivas Sarvepalli
Director/Designated Partner
over 2 years ago
over 2 years ago
Ramesh Babu Potluri
Director/Designated Partner
over 2 years ago
over 2 years ago
Vamsi Krishna Potluri
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Veeravenkata Satyanarayana Murthy Talluri
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Shravan Kudaravalli
Director/Designated Partner
about 7 years ago
about 7 years ago
Neelaveni Thummala .
Director/Designated Partner
about 11 years ago
about 11 years ago
Sarath Kumar Pakalapati
Director/Designated Partner
about 11 years ago
about 11 years ago
Past Directors
Utpal Gokhale Suhas
Nominee Director
over 13 years ago
over 13 years ago
Uma Maheswaram Kuravi
Nominee Director
over 14 years ago
over 14 years ago
Ayman Sahli
Nominee Director
over 16 years ago
over 16 years ago
Subramanyeswara Rao Kudaravalli
Director
over 20 years ago
over 20 years ago
Manoranjan Choudary Boyapati
Director
over 20 years ago
over 20 years ago
Mihir Kanti Chaudhuri
Director
about 21 years ago
about 21 years ago
Pitcheswara Rao Achanta
Director
about 31 years ago
about 31 years ago
Patents
THE INVENTION RELATES TO A NOVEL METHOD FOR THE PREPARATION PRODUCT OF FORMULA-I
WHERE
BY REACTING A NEW PRODUCT OF FORMULA-11
The present invention relates to an improved process for the preparation of o-
. Ethoxybenzamidine hydrochloride in a cost effective and industrially feasible manner.
The present invention relates to an improved process for the preparation of o-
Ethoxybenzamidine hydrochloride comprising reduction of o-Eth...
This invention describes about novel 2,4-dihydro-6,8-dinitro-l-oxo- 2-substituted-[l,2,4]-triazolo [3,4-c][l,4] benzoxazine as derivatives of formula-I possessing diuretic activity superior to furosemide and hydrochlorothaizide.
Where R is Na, K,l-4-alkyl or CH2-X where X is morpholine, piperidinyl or CH2OCOY wh...
A process for preparation of eletriptan hydrobromide having a-form of formula-I by reducing 3-(((R)-1-methylpyrrolidin-2-yl)methyl)-5-((E)-2-(phenylsulfonyl)vinyl)-1H-indole of formula-II in presence of a metal catalyst and converting to its hydrobromide salt.
ABSTRACT:
The present invention relates to an improved process for the preparation of Tenofovir,
and further conversion to Tenofovir Disoproxil or its pharmaceutically acceptable
salts thereof comprising dealkylation of phosphonate ester of Formula 11(a), using
halotrimethylsilane in the presence of a phase tran...
The objective of the present invention is to provide an improved process for the preparation of Imidapril that avoids the use of high pressure hydrogenation and gaseous hydrogen under pressure.
There is provided a process for the preparation of 1-methyl-2-oxoimidazolidine-4-carboxylate of formula (II),
the ...
The present invention relates to an improved process for the preparation of Crystalline Tadalafil Form A using solvent Acetic acid and anti-solvent Toluene resulting a high pure and consistent of Crystalline Tadalafil Form A.
The present invention provides a novel crystalline form of Eletriptan hydrobromide monohydrate. The present invention also relates to a process for the preparation of novel crystalline form of Eletriptan hydrobromide monohydrate.
The objective of the present invention is to provide an improved process for the preparation of Oxazolidinones of Formula (I):
Oxazolidinones of Formula (I) represents antibiotic drugs Linezolid, Tedizolid, Radezolid, Eperezolid, Ranbezolid, Posizolid, Sutezolid and an anticoagulant Rivaroxaban.
Particularly, th...
Synthesis of 6-hdyroxy-7-methozy quinazoline 4(3H) one, where in the quinazolinone derivative of formula - VII is prepared by converting iso vanillin (4-hydroxy-3-methoxy benzaldehyde) of formula-1 to a product of formula-II, nitrating the product of formula-II. to get a product of formula-III, conventing the produc...
Synthesis for quinazolinones of formula VII and its further conversion to an anti-cancer product, namely gefitinib of formula XIX, wherein reacting with 1-bromo-3-chloro propane to get hitherto unknown intermediate of formula XVIIIa, and converting the product formed of formula XVIII to product of XIX by reacting wi...
The present invention relates to a novel and environmentally safe and clean process for the of pharmaceutical grade anti-ulceratives, ranitidine and nizatidine, and an industrially significant by-product, thiophenol, comprising reacting a novel intermediate of formula I
with a derivative of formula II
in the prese...
The present invention relates to a process for the preparation of a novel product, 2-arylthio-2-methylamino-l-nitroethene, which in turn may be employed as a novel intermediate for the manufacture of anti-ulceratives like ranitidine and nizatidine.
The present invention provides an improved process for preparing 4-(4-methylpiperazin-1-yl)methyl benzoic acid dihydrochloride and its reaction with N-(5-amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidine amine in presence of DCC & HOBT to give imatinib. Imatinib is converted to its oxalate salt, reconverted to imatin...
The invention relates to a novel method for the preparation of imidapril hydrochloride of
formula-I
Formula-I
by reacting esters of 4(S)-1-methyl-2-oxoimidazolidine-4-carboxylate of formula-II with (S)-ethyl-2-[(S)-4-methyl-2,5-dioxooxazolidin-3-yl]-4-phe...
The present invention reveals a novel process for the one of the key intermediates of eletriptan. The process involves heck coupling of the indole derivative with phenyl vinyl sulphone to render the corresponding product.
ABSTRACT
The present invention relates to novel and improved process for preparing a Azole Antifungal agent or its pharmaceutically acceptable salts. The present invention more " particularly relates to novel and improved process for preparing Luliconazole or its pharmaceutically acceptable salts.
...
INTERMEDIATE OF IBUPROFEN
The present invention provides a simple, cost effective, improved and robust process for the preparation of compound of formula I which is used as an intermediate in the preparation of Ibuprofen or its salts, wherein the process is simple and cost effective.
Not Submitted
ABSTRACT:
Present invention relates to a process for the preparation of Tenofovir by dealkylatioh of its phosphonate esters using Urea, Thiourea Or Guanidine, through the formation of Tenofovir- adduct, followed by hydrolysis using an acid.
The present invention relates to an improved process for the preparation of Raltegravir compound of Formula (I)
Formula (I) or its salts using an intermediate compound of Formula (II)
Formula (II) or its salts, wherein Rj, and Rj' are independently selected from hydrogen, alkyl or N-protecting group, R3 is selecte...
The present invention relates to an improved process for the preparation of Apixaban intermediate compound of Formula (I)
wherein R1 is selected from halo, nitro, amino, N-protected amino, N-acyl optionally substituted with halo groups.
The present invention relates to an improved process for the purification of Luliconazole using mixture of alcohols which is highly cost effective, commercially feasible & industrially advantageous.
The present invention provides a simple, cost effective, improved and robust process for the preparation of Macitentan of Formula I.yielding, at a high yield with high purity without formation of undesired impurities.
The present invention is. to provide a simple, cost effective, improved and robust process for ' tke .preparation of Rizatriptan intermediate 4-((lH-l,2,4-triazol-l-yr)methyl)benzeiiarnine compound of Formula-I yielding at a high yield with high purity without formation of undesired impurities.
...
ABSTRACT
The. present invention relates a simple, cost effective, improved and robust process for the preparation of Dabigatran intermediate Ethyl-3-[[3-amino-4-(nrethy].arilino)bcnzoyi]-p)Tidiri-2iylarniho]propanoate compound of Formula-I yielding at a high yield with high purity without formation of undesired imp...
The present invention relates to improved process for the purification of Brexpiprazole compound of Formula I using Brexpiprazole phosphate salt.
Not submitted
ABSTRACT
NOVEL POLYMORPHS OF ELAGOLIX SODIUM
The present invention relates to novel mixture of amorphous and crystalline polymorph of Elagolix Sodium salt & its use in the preparation of pure Elagolix.
The present invention relates to novei. crystalline polymo.rph of Luliconazole HBr salt & its use in the preparation of chiraliy pure Luliconazole.
The present invention provides crystalline Ranitidine hydrochloride Form 2 with a residual isopropanol solvent below 100 ppm and contains NDMA impurity less than 0.05 ppm as measured by LC-MS/MS method.
ABSTRACT
The present invention relates a simple, cost effective, improved and robust process for the preparation of Dabigatran Etexilate from Dabigatran using imidazole as a coupling agent.
The present invention provides an improved process for the preparation of compound of Formula II which is free of Impurity A
wherein the reaction is carried out in the presence of inorganic base.
The present invention relates to novel crystalline polymorph of Lanoconazole HBr salt & its use in the preparation of pure Lanoconazole.
Registered Trademarks
[Class : 5] Pharmaceuticals, Drug Delivery Agents In The Form Of Capsules That Provide Controlled Release Of The Active Ingredients For A Wide Variety Of Pharmaceuticals As Covered Under Class 5
[Class : 5] Pharmaceuticals, Drug Delivery Agents In The Form Of Capsules That Provide Controlled Release Of The Active Ingredients For A Wide Variety Of Pharmaceuticals As Covered Under Class 5.
[Class : 5] Pharmaceutical, Veterinary And Sanitary Preparations; Dietetic Substances
Adapted For Medical Use, Food For Babies; Plasters, Materials For Dressings;
Materials For Stopping Teeth, Dental Wax; Disinfectants; Preparation For
Destroying Vermin; Fungicides, Herbicides.
Trade mark is likely to be removed due to non filing of Renewal request within prescribed time limit In case of any discripancy contact respective TM Registry.
View +15 more Brands for Sms Pharmaceuticals Limited.
Charges
02 November 2023
Others
0
24 January 2023
Idbi Bank Limited
0
20 December 2003
Uti Bank Ltd
0
26 December 2003
Uti Bank Limited
0
18 December 2003
Export Import Bank Of India
0
22 March 2003
Uti Bank Limited
0
14 March 2002
Export -import Bank Of India
0
25 January 2001
Export-import Bank Of India
0
01 July 2000
Export-import Bank Of India
0
06 August 1996
Icici Limited
0
19 July 1995
Icici Limited
0
29 March 2006
Export Import Bank Of India
0
25 September 2006
Export Import Bank Of India
0
19 October 2006
Export Import Bank Of India
0
01 June 2007
State Bank Of India
0
21 February 2008
Export-import Bank Of India
0
21 February 2008
Export -import Bank Of India
0
27 February 2009
Axis Bank Limited
0
28 August 2009
Export Import Bank Of India
0
23 July 2010
Idbi Bank Limited
0
11 March 2011
Sbi Global Factors Limited
0
11 March 2011
Sbi Global Factors Limited
0
08 July 2011
Icici Bank Limited
0
25 September 2013
Export-import Bank Of India
0
11 November 2014
Idbi Bank Limited
0
26 December 2003
Export -import Bank Of India
0
10 November 2005
Export Import Bank Of India
0
14 February 1997
Allahabad Bank
0
26 July 1985
Allahabad Bank
0
27 March 2000
State Bank Of India
0
05 March 2003
State Bank Of India
0
18 December 2004
Export-import Bank Of India
0
08 October 2004
Uti Bank Ltd
0
01 December 1984
A.p. State Financial Corporation
0
24 July 1985
Allahabad Bank
0
30 October 1986
Mid - West Leasing Ltd.
0
15 February 1988
A.p. State Financial Corporation
0
15 April 1989
A.p. State Financial Corporation
0
10 October 1991
Canara Bank
0
01 October 1994
Canara Bank
0
24 July 1995
Allahabad Bank
0
02 August 1995
Canara Bank
0
28 December 1995
Canara Bank
0
20 January 1997
Stressed Assets Stabilisation Fund
0
12 September 1997
Stressed Assets Stabilisation Fund
0
26 May 1995
Nagarjuna Finance Company Ltd.
0
20 August 1995
Nagarjuna Finance Company Ltd.
0
07 November 1988
A.p. State Finncial Corporation
0
27 July 1989
A.p. State Financial Corporation
0
26 October 1989
State Financial Corporation
0
19 April 1994
A.p.s.f.c
0
14 June 1995
Icici Limited
0
08 March 2022
Others
0
11 November 2014
Idbi Bank Limited
0
25 February 2022
State Bank Of India
0
24 June 2016
Others
0
17 June 2019
Yes Bank Limited
0
16 March 2018
Others
0
16 July 2019
Others
0
30 June 2021
Others
0
11 May 1989
State Bank Of India
0
